These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 17250897

  • 1. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.
    Halstead DC, Abid J, Dowzicky MJ.
    J Infect; 2007 Jul; 55(1):49-57. PubMed ID: 17250897
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ, Bouchillon SK, Dowzicky MJ.
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X, Dowzicky MJ.
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [Abstract] [Full Text] [Related]

  • 6. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 8. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Jul; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

  • 9. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA, Koch KM, Dowzicky MJ.
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
    Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
    [Abstract] [Full Text] [Related]

  • 12. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R, Dowzicky MJ.
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [Abstract] [Full Text] [Related]

  • 13. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ.
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [Abstract] [Full Text] [Related]

  • 14. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR, Dowzicky MJ.
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [Abstract] [Full Text] [Related]

  • 15. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 16. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2006.
    Chen WY, Jang TN, Huang CH, Hsueh PR.
    J Microbiol Immunol Infect; 2009 Aug; 42(4):317-23. PubMed ID: 19949755
    [Abstract] [Full Text] [Related]

  • 17. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H, Tan TY, Dowzicky MJ.
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS, Whitelaw A, Dowzicky MJ.
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [Abstract] [Full Text] [Related]

  • 19. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Ruzin A, Keeney D, Bradford PA.
    J Antimicrob Chemother; 2007 May; 59(5):1001-4. PubMed ID: 17363424
    [Abstract] [Full Text] [Related]

  • 20. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT, Chuang YC, Sun W, Liu YC, Cheng YJ, Lu PL, Chen CM, Hsu GJ, Jang TN, Lee CM, Chiang PC, Shi ZY, Wang LS, Kung HC, Lin HC, Liao CH, Liu JW, Huang CH, Tsao SM, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.